Premium
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia
Author(s) -
Percival MaryElizabeth M.,
Estey Elihu H.
Publication year - 2019
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.32354
Subject(s) - medicine , minimal residual disease , myeloid leukemia , oncology , disease , hematopoietic stem cell transplantation , myeloid , transplantation , clinical trial , leukemia , flow cytometry , cytogenetics , immunology , chromosome , biochemistry , chemistry , gene
Patients with acute myeloid leukemia (AML) who achieve a morphologic complete remission still can have measurable residual disease (MRD) detected by multiparametric flow cytometry, molecular methods, or cytogenetics. Such patients with MRD have a high risk of disease recurrence over a short timeframe, but optimal treatment strategies are unknown. Outcomes with conventional treatment, including allogeneic hematopoietic cell transplantation, are worse than those for patients without MRD. Herein, the authors review current strategies, including novel clinical trials, targeted toward patients with MRD.